For years, medical device manufacturers and pharmaceutical companies have struggled to combat the diversion of their products from foreign markets into the United States. Diversion jeopardizes patient safety and undercuts sales of legal products in the U.S. In 2012, a series of prescription drug diversion networks were responsible for distributing counterfeit cancer drugs across the U.S. Unfortunately, six years later, FDA and the Department of Justice have not been able to bring diversion to a halt.
This panel, which is composed of attorneys from King & Spalding’s International Trade and FDA & Life Sciences teams, will explore new strategies to combat diversion and highlight steps private companies can take to supplement government enforcement in this space.
If you have questions concerning this Roundtable Webinar, e-mail firstname.lastname@example.org.
CLE credit will be applied for in CA, GA, IL, NY, TX and, if needed, NC and VA. Attendees will receive a Uniform Certificate of Attendance via email approximately 30 days after the program to seek CLE credit in other jurisdictions. New York lawyers: This program is considered transitional and non-transitional in content. The interactive webinar format is synchronous and approved for all lawyers. King & Spalding LLP / 1180 Peachtree Street, Atlanta, GA 30309 | CA Provider # 10947.